4baseCare develops precision oncology solutions utilizing next-generation sequencing and comprehensive genomic profiling to identify specific cancer mutations in patients. Their technology addresses the need for personalized treatment options by providing tailored insights that enhance therapeutic decision-making for cancer care in the Indian population.
Funding
$9.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Cancer treatment decisions are often based on genomic data primarily derived from Caucasian populations, which may not accurately reflect the genetic profiles of other ethnicities, leading to potentially suboptimal treatment strategies. There is a need for comprehensive genomic profiling solutions tailored to specific populations to improve therapeutic decision-making and patient outcomes.
Solution
4baseCare offers precision oncology solutions that leverage next-generation sequencing (NGS) and comprehensive genomic profiling (CGP) to identify cancer mutations specific to diverse populations. Their services include NGS testing from both solid and liquid biopsies, as well as hereditary cancer gene panel analysis. The company's solutions provide oncologists with detailed insights into a patient's unique cancer profile, enabling personalized treatment plans and improved patient care. 4baseCare also offers a digital health platform called OncoBuddy, a 360-degree support system for patients in their fight against cancer.
Target Audience
The primary target audience includes oncologists, medical professionals, and patients seeking personalized cancer treatment options based on comprehensive genomic profiling.
Features
- Comprehensive genomic profiling using NGS technology for solid and liquid biopsies
- Population-specific cancer gene panels, including the TARGT Indiegene CGP Kit, designed with whole exome and transcriptome profiling
- Liquid biopsy analysis (SoLiQ) for minimally invasive cancer mutation detection
- Hereditary cancer gene panel testing to assess inherited cancer risks
- OncoBuddy: A digital health platform providing holistic support for cancer patients, including diet, psychology, and genetic counseling
- AI-based solutions for predicting accurate response biomarkers
- Clinical case studies demonstrating the role of CGP in identifying treatment options for recurrent cancers and therapy resistance